Clinical Trial

Effects of iGlarLixi Versus iGlar on Liver Fat Content in Patients With Type 2 Diabetes Mellitus Combined With Metabolic Dysfunction-associated Steatotic Liver Disease

Active, Not Recruiting Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated June 22, 2026 (before its estimated June 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a single-center, randomized, open-label, controlled clinical trial to compare the effects of a fixed-ratio combination of insulin glargine 100 U/mL plus lixisenatide (iGlarLixi) versus insulin glargine 100 U/mL (iGlar) on liver fat content in patients with Type 2 Diabetes (T2DM) and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). The study includes a 12-week treatment period.
Protocol Amendment History 1 change
critical Primary endpoint(s) modified 2026-06-23
Trial Details
NCT Number NCT07274644
Lead Sponsor The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Conditions Metabolic Dysfunction-Associated Steatotic Liver Disease, Diabetes Mellitus Type 2
Enrollment 36 participants
Start Date 2025-03-29
Primary Completion 2026-06-30 (estimated)
Study Completion 2026-07-30 (estimated)
Updated on ClinicalTrials.gov 2026-06-22